|1.||Lichtenstein, Gary R: 8 articles (07/2012 - 08/2003)|
|2.||Siegel, Corey A: 7 articles (12/2015 - 08/2010)|
|3.||Rutgeerts, Paul: 7 articles (03/2015 - 02/2009)|
|4.||Wrensch, Margaret: 7 articles (12/2012 - 10/2002)|
|5.||Cho, Sung Won: 7 articles (01/2012 - 06/2006)|
|6.||Cheong, Jae Youn: 7 articles (01/2012 - 06/2006)|
|7.||Peyrin-Biroulet, Laurent: 6 articles (12/2015 - 02/2010)|
|8.||Bousvaros, Athos: 6 articles (10/2015 - 07/2007)|
|9.||Loftus, Edward V: 6 articles (06/2015 - 12/2008)|
|10.||Gisbert, Javier P: 6 articles (09/2013 - 01/2010)|
01/01/2015 - "Newborns and young infants are at higher risk for infections than adults, and manifest suboptimal vaccine responses, motivating a search for novel immunomodulators and/or vaccine adjuvants effective in early life. "
07/01/2001 - "Breastfeeding is superior to infant formula feeding because in addition to breastmilk's nutritional advantages, it protects against infections through specific and non-specific immune factors and has long-term consequences for metabolism and disease later in life. "
02/01/1995 - "To clarify which immunological factors were more effective in preventing influenza virus infection, we measured immunological parameters induced by vaccination and infection in vivo and in vitro. "
07/01/1990 - "Such cell-free supernatant allowed us to look more closely at individual host immune factors in their relationship to protection against infection. "
05/01/1995 - "[The efficacy of the emergency prophylactic and therapeutic actions of immunomodulators in experimental filovirus infections]."
04/01/2015 - "Although IR/IDC showed strong antitumor effects such as reduction in tumor growth, increase in Th1 immune response, and improvement of survival, the therapeutic effect was further improved by combining treatments with immunomodulators. "
05/01/1984 - "As compared to controls treated with MMC followed by long term FT and immunomodulators concurrently, survival rate of those in Stage III tended to improve (P less than 0.1) and survival rate at 4.5 years in Stage III was significantly higher (p less than 0.01), although it was not improved in Stage IV. In patients with unresectable or recurrent tumor, survival time was not significantly lengthened with this therapy when compared with that in patients given BCG alone in the same treatment schedule (CCI-BCG group). "
08/01/2015 - "Immunomodulatory agents can also be injected directly into the tumor site to stimulate a systemic response capable of clearing even distal lesions; materials have been designed that entrap or slowly release immunomodulators at the tumor site, reducing systemic exposure and improving therapeutic efficacy. "
12/01/1992 - "The results indicate that combined treatment with both biological response modifiers is effective in tumor treatment."
01/01/1982 - "The Biological Response Modifiers Programme (BRMP) is a comprehensive programme of the National Cancer Institute to evaluate the therapeutic effect of biological substances that might be useful in the treatment of cancer. "
|3.||Crohn Disease (Crohn's Disease)
08/01/2006 - "Thiopurinic immunomodulators are effective for maintaining symptom remission in Crohn's disease. "
01/01/2014 - "A network meta-analysis on the efficacy of 5-aminosalicylates, immunomodulators and biologics for the prevention of postoperative recurrence in Crohn's disease."
08/01/2013 - "The great debate: stopping immunomodulators and biologics in Crohn's disease patients in remission."
08/01/2006 - "Remission on thiopurinic immunomodulators normalizes quality of life and psychological status in patients with Crohn's disease."
09/01/2014 - "The objective of this study was to analyze the accuracy of abdominal ultrasonography (AUS) in the assessment of mucosal healing in patients with Crohn's disease (CD) receiving immunomodulators and/or biological treatment, with ileocolonoscopy as the reference standard. "
|4.||Inflammatory Bowel Diseases (Inflammatory Bowel Disease)
09/01/2001 - "Immunomodulators are effective in treating inflammatory bowel disease. "
01/01/2014 - "The use of biological agents and immunomodulators for inflammatory bowel disease (IBD) has remarkably improved disease management in the current era but at the same time has increased the risk of infectious complications. "
01/01/2013 - "Patients with inflammatory bowel disease who do not respond to steroid therapy often require treatment with immunomodulators in an attempt to achieve a response and maintain remission. "
11/01/2012 - "Safety and efficacy of immunomodulators and biologics during pregnancy and lactation for the treatment of inflammatory bowel disease."
01/01/2012 - "The emergence of biologic response modifiers and earlier use of immunomodulators for inflammatory bowel disease (IBD) patients have improved outcomes. "
09/01/2011 - "Thiopurine immunomodulators in ulcerative colitis: moving forward with current evidence."
01/01/2010 - "Combination therapy with immunomodulators improves trough levels in Crohn's, and may prove to have benefits for the maintenance of biologic efficacy in ulcerative colitis."
06/01/2007 - "Some immunological factors are responsible in the pathogenesis of ulcerative colitis. "
01/01/2005 - "However, patient acceptability and proximal extent of disease dictate selection of a topical agent more than concern with rate of onset.A wide range of immunomodulators have been investigated in patients with steroid-refractory ulcerative colitis. "
07/15/2004 - "To assess the efficacy and safety of thiopurinic immunomodulators in strictly defined steroid-dependent ulcerative colitis. "
|1.||Adrenal Cortex Hormones (Corticosteroids)
|7.||Proteasome Endopeptidase Complex (Proteasome)
|8.||Antiviral Agents (Antivirals)
|9.||Anti-Bacterial Agents (Antibiotics)
|1.||Drug Therapy (Chemotherapy)
|4.||Transplantation (Transplant Recipients)